Macrophage Gene Prognostic Model for Breast Cancer Immunotherapy

A research document details a prognostic model built from macrophage-related genes using bulk and single-cell RNA sequencing data from TCGA and GEO databases. The model stratifies breast cancer patients into high- and low-risk categories and predicts immunotherapy response. The study also identifies HAGHL as a novel oncogenic driver.

Use Cases

• Validate the prognostic model's risk stratification using the described macrophage-related gene signatures.
• Assess the model's predictive ability for immunotherapy response as detailed in the results.
• Investigate the biological functions of the identified oncogene HAGHL through in vivo and in vitro experiments.
• Analyze differences in the immune microenvironment between the high-risk and low-risk patient groups defined by the model.

Strengths

• Research incorporates multi-omics analysis from authoritative public databases TCGA and GEO.
• Model development and validation are described with specific biological and clinical endpoints, including patient survival and immunotherapy response.
• Includes experimental validation of the novel oncogene HAGHL's role in breast cancer cell proliferation and invasion.

Limitations

• The primary data is a 2.3 MB DOCX file containing text and analysis, not the underlying raw sequencing or clinical datasets.
• The document format limits direct computational analysis; underlying tabular data or gene lists are not provided as separate files.
• Reproducibility depends on extracting specific gene names, model coefficients, and methodological details from the narrative text.

Provenance

Source

TCGA and GEO databases.

Collection Method

Analysis of bulk and single-cell RNA sequencing data, model development, and experimental validation.

Time Range

null

Freshness

Last updated March 2026.

Geography

null